Anti-TWEAK monoclonal antibodies inhibit this proliferation through reduction in the expression of MAPK and NF-κB signalling as well as reducing AKT and p38 levels in autosomal dominant polycystic kidney disease preclinical models [35, 36]. Here, TNFSF12 is linked to autosomal dominant polycystic kidney disease.